$CAH · CARDINAL HEALTH INC
Cardinal Health filed an 8-K disclosing a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 2032. The company also reaffirmed its fiscal year 2027 non-GAAP EPS guidance range of $12.40 to $12.60 and its long-term non-GAAP EPS growth target of 12% to 14%.
- Binding letter of intent extends pharmaceutical distribution agreements with CVS Health through June 2032.
- CVS Health is Cardinal Health's largest customer, making this a critical contract renewal.
- Company reaffirmed FY2027 non-GAAP EPS guidance of $12.40 to $12.60.
- Long-term non-GAAP EPS growth guidance of 12% to 14% also reaffirmed.
- News release issued October 1, 2026, filed as Exhibit 99.1 under Regulation FD.
Extended-hours trading shows CAH at $220.48, down 0.91% from the regular close of $222.50 — a modest fade on a largely confirmatory announcement with no guidance change.
CVS Health is Cardinal Health's largest customer, so locking in the distribution contract through 2032 eliminates a significant renewal-risk overhang and supports the long-term 12-14% EPS growth story
Pharmaceutical distribution is dominated by three players (Cardinal Health, McKesson, AmerisourceBergen), and multi-year contract extensions with major pharmacy chains are pivotal competitive moats. Locking CVS through 2032 removes a key overhang.
The binding letter of intent is not yet a definitive agreement; failure to finalize terms could reintroduce uncertainty around Cardinal Health's largest customer relationship.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.